NeuroPace (NASDAQ:NPCE – Get Free Report) had its price objective dropped by investment analysts at HC Wainwright from $20.00 to $12.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s target price suggests a potential upside of 58.73% from the company’s current price.
Several other analysts also recently weighed in on NPCE. KeyCorp dropped their target price on shares of NeuroPace from $18.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday. Mizuho initiated coverage on shares of NeuroPace in a report on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price target for the company. Weiss Ratings downgraded shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Raymond James Financial set a $21.00 price objective on shares of NeuroPace in a report on Tuesday, September 15th. Finally, Wells Fargo & Company lowered shares of NeuroPace from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $19.00 to $9.00 in a report on Friday. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, NeuroPace currently has an average rating of “Hold” and a consensus target price of $14.22.
Check Out Our Latest Research Report on NeuroPace
NeuroPace Stock Performance
Shares of NeuroPace stock opened at $7.56 on Monday. The firm has a market capitalization of $259.49 million, a P/E ratio of -13.50 and a beta of 1.98. The company has a quick ratio of 4.09, a current ratio of 5.26 and a debt-to-equity ratio of 5.15. The company has a 50 day moving average price of $13.21 and a 200 day moving average price of $14.75. NeuroPace has a 52 week low of $5.46 and a 52 week high of $19.60.
Institutional Trading of NeuroPace
Institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in NeuroPace during the 2nd quarter valued at approximately $41,000. Entropy Technologies LP purchased a new stake in shares of NeuroPace in the 3rd quarter valued at $146,000. Diversified Trust Co acquired a new stake in shares of NeuroPace in the third quarter worth $153,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of NeuroPace in the second quarter worth $157,000. Finally, Bank of America Corp DE acquired a new stake in shares of NeuroPace in the second quarter worth $322,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.
NeuroPace Company Profile
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Recommended Stories
- Five stocks we like better than NeuroPace
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
